Carbonic Anhydrase IX (CA IX) (MRQ-54) Mouse Monoclonal Antibody
SIGMA/379M-1
Product Type: Chemical
Immunohistochemistry Carbonic Anhydrase IX (CA IX) (MRQ-54) on renal cell carcinoma
| antibody form | culture supernatant |
| antibody product type | primary antibodies |
| biological source | mouse |
| clone | MRQ-54, monoclonal |
| conjugate | unconjugated |
| control | clear cell renal cell carcinoma, gallbladder epithelium |
| description | For In Vitro Diagnostic Use in Select Regions (See Chart) |
| form | buffered aqueous solution |
| isotype | IgG2b |
| manufacturer/tradename | Cell Marque™ |
| packaging | bottle of 1.0 mL predilute (379M-17) |
| bottle of 7.0 mL predilute (379M-18) | |
| vial of 0.1 mL concentrate (379M-14) | |
| vial of 0.5 mL concentrate (379M-15) | |
| vial of 1.0 mL concentrate (379M-16) | |
| Quality Level | 100  |
| 500 |
|
| shipped in | wet ice |
| species reactivity | human |
| storage temp. | 2-8°C |
| technique(s) | immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:50-1:200 |
| visualization | membranous |
| General description: | CA IX are a family of zinc containing metalloproteins that catalyze the reversible hydration of CO2. Among these, CA IX is anchored to the cell membrane and is expressed in the human gastrointestinal tract, chiefly in the stomach and gall bladder. It is interesting to note that CA IX is overexpressed in epithelial malignancies of the uterus, cervix, lung, breast, and kidney; none of the associated normal tissues express this isozyme. CA IX is said to maintain the extracellular acidic pH, thus promoting cell growth in these tumors5. Preliminary data suggest consistent immunoreactivity for anti-CA IX in clear cell renal cell carcinoma (RCC); it has sensitivity of 85% to 100% for clear cell RCC and this imparts diagnostic utility. Anti-CA IX may also play a role in distinguishing clear cell RCC from chromophobe RCC. Anti-CA IX, together with antibodies against Pax 2, Ksp-cadherin, and CD117, forms a robust panel that can be used to make this distinction. Strong diffuseto-multifocal immunostaining for anti-CA IX is observed in the large majority of urothelial carcinomas as opposed to the extremely weak and focal immunoreactivity seen in collecting duct carcinoma (CDC). Anti-CA IX can thus aid in distinguishing between urothelial carcinoma and CDC6. | ||||
| Legal Information: | Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany | ||||
| Linkage: | Carbonic Anhydrase IX (CA IX) Positive Control Slides, Product No. 379S , are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections). |
||||
| Other Notes: | For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com | ||||
| Physical form: | Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide | ||||
| Preparation Note: | Download the IFU specific to your product lot and format  Note: This requires a keycode which can be found on your packaging or product label. |
||||
| Quality: |
|
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |